NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma

(1:20)

Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS

(3:34)

Overall Survival with Pembrolizumab in Breast Cancer | NEJM

(2:27)

Advances in utilizing neoadjuvant immunotherapy in melanoma

(3:9)

The case for neoadjuvant pembrolizumab in TNBC

(1:42)

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

(1:54)

Adjuvant and Neoadjuvant Dilemmas

(27:18)

Total neoadjuvant therapy + pembrolizumab in locally-advanced rectal cancer

(2:48)

Remaining questions on the use of neoadjuvant pembrolizumab in early TNBC following KEYNOTE-522

(1:3)

Neoadjuvant pembrolizumab administered before surgery improves outcomes of melanoma patients

(2:32)

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC

(4:20)

#ESMO22 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma:SWOG S1801

(2:22)

Immunotherapy for Muscle Invasive Bladder Cancer

(19:21)

Differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy

(2:31)

ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study

(3:21)

Antibiotics impact outcomes with pembrolizumab in NSCLC patients

(2:3)

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...

(4:54)

LCMC3 primary analysis: Neoadjuvant atezolizumab in NSCLC

(2:59)

KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBC

(3:9)

PEMREC: neo-adjuvant pembrolizumab and RT in rectal cancer

(1:19)